# Reata Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/reata-pharmaceuticals

- Industry: Biotechnology
- Headquarters: Plano, US
- Website: www.reatapharma.com
- Total disclosed funding: $79M
- Latest round: Series F (Apr 13, 2009)
- Investors on record: 7

## About

Reata Pharmaceuticals, Inc., based in the US, is focused on developing innovative therapies for serious neurological and rare diseases, aiming to improve patient outcomes through advanced medical treatments.Reata Pharmaceuticals, Inc. specializes in the development of therapeutic agents targeting serious medical conditions. The company was founded in 2002 and is headquartered in Plano, Texas, US. Founded by Philip Thomas, Reata has undergone strategic decisions to enhance its product pipeline without any noted pivots or changes in business operations. The firm has raised a total of USD 7,300.00 mn through various funding rounds, with the most recent funding round being a Private Placement/Follow on in May 2016, where they raised USD 287.70 mn. To date, Reata has completed 14 deals, establishing a strong presence in the biotechnology sector.Reata Pharmaceuticals focuses on innovative therapies for serious neurological and rare diseases. Their primary products include agents that modulate cellular pathways related to oxidative stress and inflammation, addressing conditions like Friedreich's ataxia and Alport syndrome. Their therapies are mainly marketed in North America and Europe, aimed at healthcare providers and specialty pharmacies that cater to patients with complex disease needs.In the most recent fiscal year 2022, Reata Pharmaceuticals reported a revenue of USD 2,216.00 mn and an EBITDA of USD -314,103.00 mn, reflecting their financial performance within the healthcare market.Reata Pharmaceuticals is strategizing for future growth by focusing on the launch of new therapies aimed at addressing unmet medical needs in rare diseases. The proceeds from their last funding round in May 2016 will support the continued development of these products and their introduction into new regional markets beyond North America and Europe. The company is committed to utilizing its resources effectively to expand its reach and enhance its therapeutic offerings for patients by 2018.

## Funding rounds

- Series F, Apr 13, 2009, $32M — Novo Holdings, CPMG
- Series E, Jun 20, 2007, $20M — Novo Holdings, STARTech, CPMG, University of Texas System
- Series D, Apr 17, 2006, $15M — Cardinal Partners, STARTech
- Series C, Nov 11, 2004, $12M — STARTech, Cardinal Investment Company, Ojai Goliad

## Investors

- STARTech (https://capitalatlas.ai/funds/startech) — Series C, Series D, Series E
- Cardinal Investment Company — Series C
- Ojai Goliad (https://capitalatlas.ai/funds/ojai-goliad) — Series C
- Cardinal Partners (https://capitalatlas.ai/funds/cardinal-partners) — Series D
- Novo Holdings — Series E, Series F
- CPMG (https://capitalatlas.ai/funds/cpmg) — Series E, Series F
- University of Texas System — Series E